Introduction: Children with neuroblastoma have widely divergent outcomes, ranging from
cure in> 90% of patients with low risk disease to< 50% for those with high risk disease …

Neuroblastoma is the most common extracranial solid tumor in children. One subset, high-
risk neuroblastoma, is very difficult to treat and requires multi-modal therapy. Intensification …

Neuroblastoma is the most common extra-cranial solid tumor of childhood and the most
common in the first year of life. It is a unique malignancy in that infants often present with …

Exciting therapeutic targets are emerging from CRISPR-based screens of high mutational-
burden adult cancers. A key question, however, is whether functional genomic approaches …

Background High-dose chemotherapy with haemopoietic stem-cell rescue improves event-
free survival in patients with high-risk neuroblastoma; however, which regimen has the …

Background Outcomes for children with relapsed and refractory neuroblastoma are dismal.
The combination of irinotecan and temozolomide has activity in these patients, and its …

Patients with high risk neuroblastoma have a poor prognosis and survivors are often left with
debilitating long term sequelae from treatment. Even after integration of anti-GD2 …

Background A comprehensive clinical long-term survey over the complete spectrum of
neuroblatoma disease is lacking in the literature. Objective Our objective was to describe the …

A MESSAGE FROM ASCO'S PRESIDENT I am pleased to present Clinical Cancer
Advances 2017, which highlights the most promising advances in patient-oriented cancer …

BACKGROUND High‐level MYCN amplification (MNA) is associated with poor outcome and
unfavorable clinical and biological features in patients with neuroblastoma. To the authors' …